High-mobility group box 1 protein blockade suppresses development of abdominal aortic aneurysm

Journal of Cardiology

Volumn 59, Issue 3, 2012, Pages 299-306

  Kohno, Takashi ^a   Anzai, Toshihisa ^a,b   Kaneko, Hidehiro ^a   Sugano, Yasuo ^a,c   Shimizu, Hideyuki ^d   Shimoda, Masayuki ^d   Miyasho, Taku ^e   Okamoto, Minoru ^e   Yokota, Hiroshi ^e   Yamada, Shingo ^f   Yoshikawa, Tsutomu ^a   Okada, Yasunori ^d   Yozu, Ryohei ^d   Ogawa, Satoshi ^a,c   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c International University of Health and Welfare Mita Hospital   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e RAKUNO GAKUEN UNIVERSITY   (Japan)

^f SHINO TEST CORPORATION   (Japan)

Author keywords

Aneurysms; Aorta; Cytokines

Indexed keywords

CALCIUM CHLORIDE; CD68 ANTIGEN; ELASTIN; GELATINASE A; GELATINASE B; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN ANTIBODY; MESSENGER RNA; POLYCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA WALL; ARTICLE; ATTENUATION; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; SHAM PROCEDURE; TREATMENT DURATION;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CALCIUM CHLORIDE; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HMGB1 PROTEIN; HUMANS; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY;

EID: 84860478049     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.01.007     Document Type: Article

References (31)

1. Freestone T., Turner R.J., Coady A., Higman D.J., Greenhalgh R.M., Powell J.T. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995, 15:1145-1151.
2. Golledge J., Muller J., Daugherty A., Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
3. Guo D.C., Papke C.L., He R., Milewicz D.M. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci 2006, 1085:339-352.
4. Shimizu K., Mitchell R.N., Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006, 26:987-994.
5. Golledge J., Tsao P.S., Dalman R.L., Norman P.E. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation 2008, 118:2382-2392.
6. Vainas T., Lubbers T., Stassen F.R., Herngreen S.B., van Dieijen-Visser M.P., Bruggeman C.A., Kitslaar P.J., Schurink G.W. Serum C-reactive protein level is associated with abdominal aortic aneurysm size and may be produced by aneurysmal tissue. Circulation 2003, 107:1103-1105.
7. Pyo R., Lee J.K., Shipley J.M., Curci J.A., Mao D., Ziporin S.J., Ennis T.L., Shapiro S.D., Senior R.M., Thompson R.W. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000, 105:1641-1649.
8. Longo G.M., Xiong W., Greiner T.C., Zhao Y., Fiotti N., Baxter B.T. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002, 110:625-632.
9. Petersen E., Gineitis A., Wagberg F., Angquist K.A. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 2000, 20:457-461.
10. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
11. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
12. Wang H., Bloom O., Zhang M., Vishnubhakat J.M., Ombrellino M., Che J., Frazier A., Yang H., Ivanova S., Borovikova L., Manogue K.R., Faist E., Abraham E., Andersson J., Andersson U., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999, 285:248-251.
13. Andersson U., Wang H., Palmblad K., Aveberger A.C., Bloom O., Erlandsson-Harris H., Janson A., Kokkola R., Zhang M., Yang H., Tracey K.J. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000, 192:565-570.
14. Suda K., Kitagawa Y., Ozawa S., Saikawa Y., Ueda M., Ebina M., Yamada S., Hashimoto S., Fukata S., Abraham E., Maruyama I., Kitajima M., Ishizaka A. Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg 2006, 30:1755-1762.
15. Kalinina N., Agrotis A., Antropova Y., DiVitto G., Kanellakis P., Kostolias G., Ilyinskaya O., Tararak E., Bobik A. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004, 24:2320-2325.
16. Porto A., Palumbo R., Pieroni M., Aprigliano G., Chiesa R., Sanvito F., Maseri A., Bianchi M.E. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J 2006, 20:2565-2566.
17. Inoue K., Kawahara K., Biswas K.K., Ando K., Mitsudo K., Nobuyoshi M., Maruyama I. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol 2007, 16:136-143.
18. Kohno T., Anzai T., Naito K., Miyasho T., Okamoto M., Yokota H., Yamada S., Maekawa Y., Takahashi T., Yoshikawa T., Ishizaka A., Ogawa S. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res 2009, 81:565-573.
19. McCormick M.L., Gavrila D., Weintraub N.L. Role of oxidative stress in the pathogenesis of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2007, 27:461-469.
20. Tang D., Shi Y., Kang R., Li T., Xiao W., Wang H., Xiao X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 2007, 81:741-747.
21. Liu K., Mori S., Takahashi H.K., Tomono Y., Wake H., Kanke T., Sato Y., Hiraga N., Adachi N., Yoshino T., Nishibori M. Anti-high mobility group box 1 monoclonal antibody ameliorates brain infarction induced by transient ischemia in rats. FASEB J 2007, 21:3904-3916.
22. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
23. Qiu J., Xu J., Zheng Y., Wei Y., Zhu X., Lo E.H., Moskowitz M.A., Sims J.R. High-mobility group box 1 promotes metalloproteinase-9 upregulation through Toll-like receptor 4 after cerebral ischemia. Stroke 2010, 41:2077-2082.
24. Yoshimura K., Aoki H., Ikeda Y., Fujii K., Akiyama N., Furutani A., Hoshii Y., Tanaka N., Ricci R., Ishihara T., Esato K., Hamano K., Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005, 11:1330-1338.
25. Kaneko H., Anzai T., Morisawa M., Kohno T., Nagai T., Anzai A., Takahashi T., Shimoda M., Sasaki A., Maekawa Y., Yoshimura K., Aoki H., Tsubota K., Yoshikawa T., Okada Y., et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 2011, 217:350-357.
26. Zhang F., Kent K.C., Yamanouchi D., Zhang Y., Kato K., Tsai S., Nowygrod R., Schmidt A.M., Liu B. Anti-receptor for advanced glycation end products therapies as novel treatment for abdominal aortic aneurysm. Ann Surg 2009, 250:416-423.
27. Nakashima H., Aoki M., Miyake T., Kawasaki T., Iwai M., Jo N., Oishi M., Kataoka K., Ohgi S., Ogihara T., Kaneda Y., Morishita R. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004, 109:132-138.
28. Hofmann Bowman M., Wilk J., Heydemann A., Kim G., Rehman J., Lodato J.A., Raman J., McNally E.M. S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res 2009, 106:145-154.
29. Juvonen J., Surcel H.M., Satta J., Teppo A.M., Bloigu A., Syrjälä H., Airaksinen J., Leinonen M., Saikku P., Juvonen T. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997, 17:2843-2847.
30. Soeki T., Niki T., Kusunose K., Bando S., Hirata Y., Tomita N., Yamaguchi K., Koshiba K., Yagi S., Taketani Y., Iwase T., Yamada H., Wakatsuki T., Akaike M., Sata M. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol 2011, 58:151-157.
31. Nakamura Y., Yamada Y., Shimomura H., Nagayoshi Y., Tsujita K., Yamashita T., Fukuda M., Ohba K., Nako H., Ogura Y., Chitose T., Yamaguchi M., Nagata T., Soejima H., Kaikita K., et al. Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction. J Cardiol 2009, 54:416-424.